PhD, Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
NBE-Therapeutics has announced that it has completed a capital increase as part of a series A financing round led by Boehringer Ingelheim Venture Fund (BIVF) as lead investor. This series A financing round provides CHF 3.0 million new working capital for NBE-Therapeutics, the press release states.
These funds should finance the development of a portfolio of first Antibody Drug Conjugate (ADC) development candidates, after the company has successfully completed a number of technology validation milestones during the first 2,5 years since incorporation.
NBE-Therapeutics’ fully validated technologies include its enzymatic antibody-payload conjugation platform «SMAC-TechnologyTM» and its antibody discovery and engineering platform «Transpo-mAb technologyTM», which has recently been granted as a European patent.
NBE-Therapeutics has raised CHF 2.5 million of seed funding during its first 2.5 years of operations, which started in mid-2012, the press release states. Now, the company has raised CHF 5.5 million funds from its investors, complemented by CHF 4.0 million in funding from research grants for various academic collaborations with e.g. ETH Zürich, University Hospital Basel and the Technical University for Life Sciences North-Western Switzerland, as well as from a FP7 «Research for SMEs» EU-grant.
The complete media release by NBE-Therapeutics